Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration with emtricitabine/tenofovir-DF has not been studied. Coadministration of emtricitabine and famciclovir decreased famciclovir AUC and Cmax by 9% and 7% and decreased emtricitabine AUC and Cmax by 7% and 11%. Coadministration with tenofovir-DF has not been studied but may result in increased concentrations of famciclovir and tenofovir due to competition for active tubular secretion. No a priori dosage adjustment is recommended, but renal function should be monitored.
Coadministration of famciclovir and emtricitabine decreased famciclovir AUC and Cmax by 9% and 7%. Emtricitabine AUC and Cmax decreased by 7% and 11%. No dose adjustment of famciclovir is required.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
No clinically significant drug interactions have been observed between FTC and famciclovir. Coadministration of famciclovir (500 mg single dose) and emtricitabine (200 mg single dose) was studied in 12 subjects. There was no change in the Cmax and AUC of emtricitabine or famciclovir.
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking